View in EDS

Comparison of annual versus twice-yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster-randomised trial.

Saved in:
Bibliographic Details
Title: Comparison of annual versus twice-yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster-randomised trial.
Authors: Gebre T (AUTHOR), Ayele B (AUTHOR), Zerihun M (AUTHOR), Genet A (AUTHOR), Stoller NE (AUTHOR), Zhou Z (AUTHOR), House JI (AUTHOR), Yu SN (AUTHOR), Ray KJ (AUTHOR), Emerson PM (AUTHOR), Keenan JD (AUTHOR), Porco TC (AUTHOR), Lietman TM (AUTHOR), Gaynor BD (AUTHOR), Gebre, Teshome (AUTHOR), Ayele, Berhan (AUTHOR), Zerihun, Mulat (AUTHOR), Genet, Asrat (AUTHOR), Stoller, Nicole E (AUTHOR), Zhou, Zhaoxia (AUTHOR)
Source: Lancet. 1/14/2012, Vol. 379 Issue 9811, p143-151. 9p.
Abstract: Background: In trachoma control programmes, azithromycin is distributed to treat the strains of chlamydia that cause ocular disease. We aimed to compare the effect of annual versus twice-yearly distribution of azithromycin on infection with these strains.Methods: We did a cluster-randomised trial in 24 subdistricts in northern Ethiopia, which we randomly assigned to receive annual or twice-yearly treatment for all residents of all ages. Random assignment was done with the RANDOM and SORT functions of Microsoft Excel. All individuals were offered their assigned treatment of a single, directly observed, oral dose of azithromycin. A 6 week course of topical 1% tetracycline ointment, applied twice daily to both eyes but not directly observed, was offered as an alternative to azithromycin in patients younger than 12 months, and in patients with self-reported pregnancy, with allergy, or who refused azithromycin. Our primary, prespecified outcome was the prevalence of ocular chlamydial infection in a random sample of children aged 0-9 years at baseline and every 6 months for a total of 42 months within sentinel villages. Our analysis was by intention to treat. This study is registered with ClinicalTrials.gov, number NCT00322972.Findings: Antibiotic coverage of children aged 1-9 years was greater than 80% (range 80·9 to 93·0) at all study visits. In the groups treated annually, the prevalence of infection in children aged 0-9 years was reduced from a mean 41·9% (95% CI 31·5 to 52·2) at baseline to 1·9% (0·3 to 3·5) at 42 months. In the groups treated twice yearly, the prevalence of infection was reduced from a mean 38·3% (29·0 to 47·6) at baseline to 3·2 % (0·0 to 6·5) at 42 months. The prevalence of ocular chlamydial infection in children aged 0-9 years in groups treated annually was not different from that of the groups treated twice yearly at 18, 30, and 42 months (pooled regression p>0·99, 95 % CI -0·06 to 0·06). The mean elimination time in the twice-yearly treatment group was 7·5 months earlier (2·3 to 17·3) than that of the annual group (p=0·10, Cox proportional hazards model).Interpretation: After 42 months of treatment, the prevalence of ocular infection with chlamydia was similar in the groups treated annually and twice yearly. However, elimination of infection might have been more rapid in the groups of villages that received treatment twice yearly.Funding: National Institutes of Health (NEI U10 EY016214). [ABSTRACT FROM AUTHOR]
Copyright of Lancet is the property of Lancet and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
FullText Text:
  Availability: 0
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 108220365
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Comparison of annual versus twice-yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster-randomised trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Gebre+T%22">Gebre T</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Ayele+B%22">Ayele B</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Zerihun+M%22">Zerihun M</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Genet+A%22">Genet A</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Stoller+NE%22">Stoller NE</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Zhou+Z%22">Zhou Z</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22House+JI%22">House JI</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Yu+SN%22">Yu SN</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Ray+KJ%22">Ray KJ</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Emerson+PM%22">Emerson PM</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Keenan+JD%22">Keenan JD</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Porco+TC%22">Porco TC</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Lietman+TM%22">Lietman TM</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Gaynor+BD%22">Gaynor BD</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Gebre%2C+Teshome%22">Gebre, Teshome</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Ayele%2C+Berhan%22">Ayele, Berhan</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Zerihun%2C+Mulat%22">Zerihun, Mulat</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Genet%2C+Asrat%22">Genet, Asrat</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Stoller%2C+Nicole+E%22">Stoller, Nicole E</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Zhou%2C+Zhaoxia%22">Zhou, Zhaoxia</searchLink> (AUTHOR)
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Lancet%22">Lancet</searchLink>. 1/14/2012, Vol. 379 Issue 9811, p143-151. 9p.
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: <bold>Background: </bold>In trachoma control programmes, azithromycin is distributed to treat the strains of chlamydia that cause ocular disease. We aimed to compare the effect of annual versus twice-yearly distribution of azithromycin on infection with these strains.<bold>Methods: </bold>We did a cluster-randomised trial in 24 subdistricts in northern Ethiopia, which we randomly assigned to receive annual or twice-yearly treatment for all residents of all ages. Random assignment was done with the RANDOM and SORT functions of Microsoft Excel. All individuals were offered their assigned treatment of a single, directly observed, oral dose of azithromycin. A 6 week course of topical 1% tetracycline ointment, applied twice daily to both eyes but not directly observed, was offered as an alternative to azithromycin in patients younger than 12 months, and in patients with self-reported pregnancy, with allergy, or who refused azithromycin. Our primary, prespecified outcome was the prevalence of ocular chlamydial infection in a random sample of children aged 0-9 years at baseline and every 6 months for a total of 42 months within sentinel villages. Our analysis was by intention to treat. This study is registered with ClinicalTrials.gov, number NCT00322972.<bold>Findings: </bold>Antibiotic coverage of children aged 1-9 years was greater than 80% (range 80·9 to 93·0) at all study visits. In the groups treated annually, the prevalence of infection in children aged 0-9 years was reduced from a mean 41·9% (95% CI 31·5 to 52·2) at baseline to 1·9% (0·3 to 3·5) at 42 months. In the groups treated twice yearly, the prevalence of infection was reduced from a mean 38·3% (29·0 to 47·6) at baseline to 3·2 % (0·0 to 6·5) at 42 months. The prevalence of ocular chlamydial infection in children aged 0-9 years in groups treated annually was not different from that of the groups treated twice yearly at 18, 30, and 42 months (pooled regression p>0·99, 95 % CI -0·06 to 0·06). The mean elimination time in the twice-yearly treatment group was 7·5 months earlier (2·3 to 17·3) than that of the annual group (p=0·10, Cox proportional hazards model).<bold>Interpretation: </bold>After 42 months of treatment, the prevalence of ocular infection with chlamydia was similar in the groups treated annually and twice yearly. However, elimination of infection might have been more rapid in the groups of villages that received treatment twice yearly.<bold>Funding: </bold>National Institutes of Health (NEI U10 EY016214). [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of Lancet is the property of Lancet and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=108220365
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/S0140-6736(11)61515-8
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 9
        StartPage: 143
    Titles:
      – TitleFull: Comparison of annual versus twice-yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster-randomised trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Gebre T
      – PersonEntity:
          Name:
            NameFull: Ayele B
      – PersonEntity:
          Name:
            NameFull: Zerihun M
      – PersonEntity:
          Name:
            NameFull: Genet A
      – PersonEntity:
          Name:
            NameFull: Stoller NE
      – PersonEntity:
          Name:
            NameFull: Zhou Z
      – PersonEntity:
          Name:
            NameFull: House JI
      – PersonEntity:
          Name:
            NameFull: Yu SN
      – PersonEntity:
          Name:
            NameFull: Ray KJ
      – PersonEntity:
          Name:
            NameFull: Emerson PM
      – PersonEntity:
          Name:
            NameFull: Keenan JD
      – PersonEntity:
          Name:
            NameFull: Porco TC
      – PersonEntity:
          Name:
            NameFull: Lietman TM
      – PersonEntity:
          Name:
            NameFull: Gaynor BD
      – PersonEntity:
          Name:
            NameFull: Gebre, Teshome
      – PersonEntity:
          Name:
            NameFull: Ayele, Berhan
      – PersonEntity:
          Name:
            NameFull: Zerihun, Mulat
      – PersonEntity:
          Name:
            NameFull: Genet, Asrat
      – PersonEntity:
          Name:
            NameFull: Stoller, Nicole E
      – PersonEntity:
          Name:
            NameFull: Zhou, Zhaoxia
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 14
              M: 01
              Text: 1/14/2012
              Type: published
              Y: 2012
          Identifiers:
            – Type: issn-print
              Value: 01406736
          Numbering:
            – Type: volume
              Value: 379
            – Type: issue
              Value: 9811
          Titles:
            – TitleFull: Lancet
              Type: main
ResultId 1